Drug portfolio Liquidia focuses on YUTREPIA treprostinil inhalation for PAH and PH-ILD, plus L606 liposomal treprostinil in development. Opportunity: align with specialty distributors and payer strategies for pulmonary hypertension therapies to expand access and accelerate adoption.

Manufacturing capability Recent $50M investment to expand manufacturing and accelerate launch execution. Opportunity: position as a partner for contract manufacturing or shared production milestones to support scalable commercialization of inhalation therapies.

Financial momentum Reported net income in Q1 2026 and ongoing growth in Yutrepia uptake indicate improving profitability and market adoption. Opportunity: engage with finance and procurement teams to explore value-based pricing discussions and future supply agreements.

Clinical visibility Active participation in major pulmonary conferences and PVRI congress with multiple poster presentations demonstrates ongoing clinical validation efforts. Opportunity: collaborate on investigator-initiated studies, real-world evidence generation, and targeted KOL engagements to support reimbursement dossiers.

Strategic partnerships Recent collaboration with Team Phenomenal Hope and LMBYL highlights a patient-centric and community-focused approach. Opportunity: leverage patient advocacy channels and outcomes data to accelerate market access and expand in rare cardiopulmonary indications.